Mirum (MIRM) Q1 2025 Earnings Call Transcript

Mirum reported Q1 net product revenue of $111.6M, up 61% YoY, and raised full-year revenue guidance to $435M–$450M. LIVMARLI global sales were $73.2M (up >70% YoY; U.S. $49.5M, international $23.7M with ~$6M inventory build), bile acid product sales $38.4M (+47% YoY), and cash/investments totaled $298.6M. The company recorded operating expenses of $126.8M (R&D $46M including $7M one-time milestones; SG&A $57.7M), was cash-flow positive for the quarter and expects full-year positive cash flow, and noted improved cash contribution margin to ~53% (from ~47%). Management highlighted three regulatory approvals (including CTEXLI FDA approval and a single-tablet LIVMARLI with expected patent protection to 2043), positive VANTAGE interim pruritus data (3.8-point baseline reduction, 2.5-point placebo-adjusted), VISTAS enrollment completion expected Q3 2025 with topline in Q2 2026, and a Phase 2 MRM-3379 start planned this year.

Analysis

Mirum's recent trajectory creates two asymmetric levers: formulation/IP control and channel dynamics. The expected long-dated formulation patent materially raises the marginal lifetime value of older pediatric and adult patients by reducing churn and enabling a pricing/packaging shift (single-tablet convenience), which increases sticky revenue per patient and raises barriers for near-term entrants — this is structural leverage to revenue and gross-margin expansion if uptake follows through.

Conversely, the appearance of partner/distributor inventory build in a recent quarter introduces a classic channel-fill distortion: near-term upside in reported international sales could be followed by a 1–2 quarter revenue softening if pull-through lags. That amplifies quarter-to-quarter volatility and makes headline growth a noisier input for short-term models; investors should therefore separate order-driven revenue from underlying prescription pull-through when forecasting.

Financially, an improved cash-contribution margin combined with operating cash-positivity materially lowers dilution risk and gives management optionality to fund confirmatory programs and commercial scale-up without near-term capital raises. However, GAAP profitability remains clouded by recurring stock-based comp and milestone cadence; treat free-cash-flow trajectory as the cleaner metric for valuation and capital-allocation decisions.

The program-level risk is classic biotech binary: confirmatory readouts and reimbursement decisions compress upside into distinct events, while the patent and partner footprint provide asymmetric downside protection versus many small-cap peers. Key near-term drivers are execution on commercial pull-through and successful confirmatory outcomes; payer behavior around a tablet formulation and potential generic/design-around litigation are the main tail risks to model carefully.

Key Decisions for Investors

• Long MIRM shares (total position size 2–4% of equity book) established in tranches; add into any pullback funded by realized volatility spikes. Hedge with 3–6 month MIRM put protection ~25–30% OTM (purchase put or put spread) to cap downside from an event-driven miss — trade R/R: asymmetry of meaningful upside on positive confirmatory signals vs limited net downside after hedging.
• Event-driven call spread: buy Jan-2026 MIRM LEAP call and sell a nearer-dated call (e.g., Jan-2025) to finance premium; use this if you want convex exposure to the binary readouts while limiting premium outlay. Target 2–3x notional payoff on successful data, loss limited to net premium.
• Pair trade to remove sector beta: go long MIRM (as above) and short a biotech ETF (eg IBB) sized ~30–40% of long notional to isolate stock-specific upside from broad-market biotech moves. This reduces sensitivity to broad risk-off and focuses P/L on Mirum-specific execution.
• Tactical downside hedge if you prefer event insurance: buy a Sep-2025 MIRM put spread (e.g., buy 35% OTM / sell 50% OTM) sized to cover expected headline reversal from distributor pull-through normalization. This is a cheaper insurance play to protect Q3–Q4 exposure while keeping upside intact.